



Satureja khuzestanica prevents the development of morphine analgesic tolerance through suppression of spinal glial cell activation in rats

Saeed Esmaeili-Mahani · Bahareh Ebrahimi ·
Mehdi Abbasnejad · Bahram Rasoulian ·
Vahid Sheibani

Received: 12 January 2013 / Accepted: 30 July 2013
© The Japanese Society of Pharmacognosy and Springer Japan 2013

Abstract Glial cell activation and oxidative stress are important factors in the induction of opioid side effects such as tolerance and dependence. It has been demonstrated that *Satureja khuzistanica* extract (SKE) has anti-oxidative, antinociceptive and anti-inflammatory properties; however, its influences on opioid analgesic tolerance have not yet been clarified. Adult male Wistar rats were rendered analgesic-tolerant by injection of 10 mg/kg morphine twice daily for 8 days. To determine the effect of SKE on the development of morphine tolerance, different doses of SKE (25, 50 and 100 mg/kg i.p.) were injected simultaneously with morphine. The tail-flick test was used to assess the nociceptive threshold. The lumbar spinal cord was assayed to determine glial fibrillary acidic protein (GFAP) and tumor necrosis factor alpha (TNF α) levels by the Western blotting method. Our results showed that chronic morphine produced tolerance to the antinociceptive effect of morphine. However, SKE could prevent, in a dose-dependent manner, morphine tolerance development. In tolerant animals, a significant increase in GFAP and TNF α levels was observed in the lumbar spinal cord, and was reversed to control levels by 100 mg/kg

SKE. Our data revealed that *Satureja khuzistanica* had beneficial effects in preventing opioid tolerance and the underlying mechanisms of those effects may be due, at least in part, to reduce spinal glial cell activation.

Keywords *Satureja khuzistanica* extract · Morphine · Analgesic tolerance · Spinal cord · GFAP · TNF α

Introduction

The chronic use of opioids such as morphine leads to antinociceptive tolerance, which limits their serviceable and therapeutic effects. Many mechanisms are involved in the induction of analgesic tolerance development [1].

Within the past 20 years evidence has shown that the immune system can alter neuronal function. The effects of immune/glial cells on pain and opioid action occur on multiple levels [2]. Both glial (microglia and astrocyte) activation and enhanced pro-inflammatory cytokine levels were observed following chronic morphine treatment at the lumbar spinal cord of the rats [3]. In addition, following chronic morphine, a marked glial response, astroglial hypertrophy and increased expression of glial fibrillary acidic protein (GFAP) were observed in the spinal cord, posterior cingulate cortex, and hippocampus [4]. The activation of glial cells and enhanced pro-inflammatory cytokine expression has been implicated in the development of morphine tolerance and morphine-induced hyperalgesia [5]. Surprisingly, inhibition of glial activation or antagonizing the activity of pro-inflammatory cytokines interleukin (IL)-1 β , IL-6 and tumor necrosis factor alpha (TNF α) attenuated the development of morphine tolerance and withdrawal-induced hyperalgesia in rats [4, 6].

S. Esmaeili-Mahani · V. Sheibani
Laboratory of Molecular Neuroscience, Kerman Neuroscience
Research Center (KNRC), Kerman University of Medical
Sciences, Kerman, Iran

S. Esmaeili-Mahani (✉) · B. Ebrahimi · M. Abbasnejad
Department of Biology, Faculty of Sciences, Shahid Bahonar
University of Kerman, P.O.Box: 76135-133, Kerman, Iran
e-mail: semahani@yahoo.com; semahani@uk.ac.ir

B. Rasoulian
Razi Herbal Medicines Research Center, Lorestan University of
Medical Sciences, Khoramabad, Iran

Recently, the demonstration of anti-addictive, anti-tolerance and antinociceptive properties of natural herbal products has attracted intense interest [7]. However, natural products need precise scientific experimental testing as well as clinical trials before they can be used in the management of opioid side effects.

Satureja khuzistanica Jamzad (Marzeh Khuzestani in Persian, family Lamiaceae) is an endemic plant that is widely distributed in the southern part of Iran. It is famous for its medical uses as analgesic and antiseptic in folk medicine [8]. Amanlou and colleagues [9] confirmed that the anti-inflammatory and antinociceptive properties of *Satureja khuzistanica* are comparable to those of indomethacin and morphine. Furthermore, this plant has antihyperalgesic effects in a rat model of diabetic neuropathy [10]. In Persian traditional medicine *satureja* is used for treating muscle and neuropathic pain as well as withdrawal-induced pain and related side effects.

Based on the fact that glial activation and oxidative stress occur following chronic usage of opioids and those factors play important roles in the induction of opioid tolerance, and that *Satureja khuzistanica* has antioxidant, antinociceptive and anti-inflammatory properties, the present study was designed to test the hypothesis that its extract could exert effects on the induction of morphine antinociceptive tolerance and also to determine its possible mechanism in that phenomenon.

Materials and methods

Animals

All experiments were carried out on male Wistar rats, weighing 200–250 g, that were housed under a 12 h light/dark cycle in a room with controlled temperature (22 ± 1 °C) and free access to food and water. Animals were handled daily (between 9:00 and 10:00 AM) for 3 days before the experiment days in order to adapt them to manipulation and minimize nonspecific stress responses. Rats were divided randomly into several experimental groups, each comprising 6–8 animals. All experiments followed the guidelines on ethical standards for investigation of experimental pain in animals [11] and were approved by the Animal Experimentation Ethic Committee of Kerman Neuroscience Research Center (EC/KNRC/91).

Preparation of *satureja* extract

An ethanolic *Satureja khuzistanica* extract (SKE) was prepared in Razi Herbal Medicines Research Center (Lorestan, Iran). The healthy leaves were dried in shade conditions, and to avoid decomposition of chemical

constituents dried leaves were powdered and stored in clean and dry airtight containers for further studies. A sample was deposited at the herbarium of Razi Herbal Medicines Research Center. Two hundred grams of the air-dried leaves were ground into fine powder. The powder was extracted twice, on each occasion with 1 L of 80 % ethyl alcohol. The collective ethanol extract was filtered, and the filtrate was concentrated to dryness under reduced pressure in a rotary evaporator; the resulting ethanol extract was freeze-dried. Gas chromatography–mass spectroscopy (GC-MS) analysis of the extract showed that carvacrol (78.3 %), 9-octadecenoic acid (13.5 %), hexadecanoic acid (6.7 %), bis(2-ethylhexyl)phthalate (1.0 %) and beta-bisabolene (0.5 %) were the main components of the SKE [10].

Drugs

Aliquot portions of the crude SKE were weighed and dissolved in warm physiological saline for use on each day of our experiments. Morphine hydrochloride (TEMAD, Iran) was also dissolved in physiological saline. SKE was given intragastrically (i.g.) by gavage and morphine was injected intraperitoneally (i.p.). These drugs were given in 1 ml/kg volumes (i.g. and i.p.). Control animals received saline in an equal volume (1 ml/kg).

Antinociceptive test

Antinociception was assessed by the tail-flick test [12]. Radiant heat (power intensity = 7) was focused on 4–7 cm from the tail distal end. The tail-flick latency for each rat was determined three times and the mean was designated as baseline latency before drug injection. The intensity of the beam was adjusted to produce a mean control reaction time between 2 and 4 s. The cut-off time was fixed at 10 s in order to avoid any damage to the tail. The percentage of antinociception was determined with the following formula:

$$\% \text{Antinociception (\% MPE)} = (\text{reaction time of test} - \text{basal reaction time}) / (\text{cut-off time} - \text{basal reaction time}).$$

Morphine tolerance

To induce analgesic tolerance, morphine at a daily dose of 20 mg/kg in two equally divided doses was administered at 8.00 AM and 6.00 PM from day 1 to day 8. SKE or vehicle was given according to the same schedule as control groups. Nociceptive testing was performed both before and 30 min after morphine administration on days 1, 3, 6 and 8 [13, 14]. To determine the effect of *satureja* on the development of morphine tolerance, SKE (25, 50 and

100 mg/kg i.g.) was injected simultaneously with morphine but on days that nociceptive testing was measured, morphine was injected first and antinociception was measured 30 min after morphine administration and then SKE was given. With such a method, compounds with antinociceptive properties cannot produce a false-positive anti-tolerance effect.

Tissue extraction and preparation

Rats were anesthetized (exposed to a CO₂ atmosphere) and decapitated. The spinal column was cut through the pelvic girdle. Hydraulic extrusion was performed by inserting a 16-gauge needle into the sacral vertebral canal and expelling with ice-cold saline. The spinal cord was immediately placed on ice in a glass petri dish, and the dorsal half of the lumbar cord was dissected. Tissue samples were weighed and immediately frozen in liquid nitrogen and stored at -70 °C until assay.

Western blot analysis

The dissected spinal tissues were homogenized in ice-cold buffer containing 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 0.1 % SDS, 0.1 % Na-deoxycholate, 1 % NP-40 with protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 2.5 µg/ml leupeptin, 10 µg/ml aprotinin) and 1 mM sodium orthovanadate. The homogenate was centrifuged at 14,000 g for 15 min at 4 °C. The resulting supernatant was retained as the whole cell fraction. Equal amounts of protein were electrophoresed on 9 % SDS-PAGE gel and transferred to nitrocellulose membranes (Hybond ECL, GE Healthcare Bio-Sciences Corporation, NJ, USA). After blocking (overnight at 4 °C) with 5 % non-fat dried milk in Tris-buffered saline with Tween 20 (blocking buffer, TBS-T, 150 mM

NaCl, 20 mM Tris-HCl, pH 7.5, 0.1 % Tween 20), the membranes were probed with primary antibodies (1:1000 GFAP and TNFα, Santa Cruz Biotechnology, USA) for 2 h at room temperature. After washing in TBS-T (three times for 5 min), the blots were incubated for 60 min at room temperature with a horseradish peroxidase-conjugated secondary antibody (1:15000, Santa Cruz Biotechnology). All antibodies were diluted in blocking buffer. The antibody-antigen complexes were detected using the ECL system and exposed to Lumi-Film chemiluminescent detection film (Roche, Germany). LabWorks software (UVP, UK) was used to analyze the intensity of the expression. β-Actin immunoblotting (antibody from Cell Signaling Technology, Inc., Beverly, MA, USA; 1:1000) was used to control for loading.

Statistical analysis


The results are expressed as mean ± SEM. The difference in % MPE (antinociception) between groups over the time course of study was determined by two- or one-way analysis of variance (ANOVA) followed by the Newman-Keuls test. The values of protein band density obtained from gel analysis and band densitometry were calculated. These values were expressed as GFAP or TNFα subunit/β-actin ratio for each sample. The averages for different groups were compared using ANOVA followed by the Newman-Keuls test. $P < 0.05$ was considered significant.

Results

Effect of SKE on development of tolerance to analgesic effect of morphine.

As shown in Fig. 1, chronic administration of 10 mg/kg morphine (twice daily for 8 days), induced a significant

Fig. 1 The effect of different doses (25, 50 and 100 mg/kg, i.g.) of *Satureja khuzestanica* extract (SKE) on the development of tolerance to the analgesic effect of morphine (Mor) in rats. Values represent mean ± SEM ($n = 6-8$). * $P < 0.05$, *** $P < 0.001$ significantly different versus antinociception values on the first day in the same group. + $P < 0.01$, +++ $P < 0.001$ significantly different versus morphine-injected rats at the same time






Fig. 2 The antinociceptive effect of 10 mg/kg (i.p.) morphine (*Mor*) on day 8 in groups that received morphine (10 mg/kg twice daily, i.p.) and morphine concurrently with 50 and 100 mg/kg SKE (i.g.) for 7 days. Each bar represents mean \pm SEM ($n = 6-8$). *** $P < 0.001$ significantly different versus control saline-treated group (*Cont*). +++ $P < 0.001$ significantly different versus morphine-treated animals




Fig. 3 The levels of GFAP in dorsal portion of lumbar spinal cord in control, chronic morphine-treated (10 mg/kg, i.p.) and morphine + SKE (10 mg/kg, i.p. + 100 mg/kg, i.g.) treated rats. Each value in the graph represents the mean \pm SEM band density ratio for each group ($n = 5-6$). β -Actin was used as an internal control. ** $P < 0.01$ significantly different versus control group (*Cont*). + $P < 0.05$ significantly different versus morphine-treated group (*Mor*)

decrease in its analgesic effect (tolerance). Simultaneous treatment with morphine and SKE in doses of 50 and 100 mg/kg could significantly prevent the development of tolerance to the analgesic effect of morphine. 25 mg/kg of SKE had a moderate anti-tolerance effect. However, vehicle treatment (saline) had no anti-tolerance effect (data not shown).

As shown in Fig. 2, on day 8 of the experiment, the analgesic effect of 10 mg/kg morphine in animals that




Fig. 4 Western blot analysis of TNF α in dorsal portion of lumbar spinal cord of animals that received morphine (10 mg/kg, i.p.) alone and morphine concurrently with 100 mg/kg SKE (i.g.) for 7 days. Each value in the graph represents the mean \pm SEM band density ratio for each group ($n = 5-6$). *** $P < 0.001$ compared to control animals (*Cont*); + $P < 0.05$ compared to morphine-treated group (*Mor*)

received different doses of SKE plus morphine was significantly greater than that of chronic morphine-injected rats.

Effect of morphine and morphine plus SKE on levels of GFAP and TNF α .

Immunoblotting data revealed that chronic morphine resulted in elevation of GFAP in the dorsal portion of rat lumbar spinal cord. Administration of an effective anti-tolerance dose of SKE (100 mg/kg i.g.) prevented chronic morphine-induced GFAP activation (Fig. 3).

In addition, under morphine-tolerant conditions an increase in TNF α protein levels was induced. The increased TNF α level was reversed in the rats that received morphine plus 100 mg/kg SKE (Fig. 4).

Discussion

In the present study, chronic morphine injection induced significant increases in the spinal levels of GFAP and TNF α which were accompanied by a dramatic decrease in morphine analgesia. SKE (100 mg/kg i.g.) not only attenuated the morphine-induced GFAP and TNF α expression but also prevented the induction of tolerance to the antinociceptive effect of morphine.

The underlying mechanisms involved in the induction of opioid tolerance are a very complex issue. They include modulation of intracellular adenylyl cyclase and cyclic adenosine monophosphate-dependent protein kinase A, G

protein uncoupling, increased binding of β -arrestin to opioid receptors, and μ -opioid receptor internalization [15]. In addition, activation of *N*-methyl-D-aspartate receptor, downregulation of glutamate transporters, upregulation of L-type calcium channels, and glial cell activation with increasing pro-inflammatory cytokine expression and apoptosis have also been observed in tolerance situations [16–19].

Glial cell activation and increased cytokine (TNF α , IL-1 β , and IL-6) expression have important roles in the pathogenesis of morphine tolerance and suppression of such events could be helpful in the prevention of analgesic tolerance [20, 21].

It is well known that *Satureja khuzestanica* has a potent anti-inflammatory effect in an animal model of inflammatory pain [9]. The results of this study demonstrated that SKE attenuates morphine-induced elevation in TNF α level. The increase in TNF α expression in the spinal cord of morphine-treated rats contributed to cytokine-mediated neuroinflammation and the subsequent neuronal plasticity [22]. Therefore, it seems that the attenuation of morphine-induced TNF α over-expression by SKE is a possible mechanism for its anti-tolerance effect.

Glial fibrillary acidic protein is expressed in the central nervous system in astrocyte cells and is involved in many important processes. Previous evidence demonstrated that increased expression of GFAP is observed in the central nervous system of chronic morphine-treated animals and this phenomenon plays a fundamental role in the development of opioid complications and side effects, i.e., tolerance and dependence [4]. It has been shown that glia have a central role in the development of morphine tolerance and that administration of a glial modulating agent attenuated tolerance formation [23].

Recently, Jin and colleagues [24] showed that LXA4ME, a lipoxin A4 analogue, attenuates morphine analgesic tolerance and inhibits the activation of microglia and astrocytes through the reduction of pro-inflammatory cytokines (IL-1 β , IL-6, and TNF α) at the lumbar spinal cord. Furthermore, it has been reported that inhibition of ceramide biosynthesis with various pharmacological inhibitors significantly blocks the development of morphine antinociceptive tolerance through attenuation of spinal glial activation, IL-1 β , IL-6, and TNF α [25].

It is well known that such pro-inflammatory cytokines can enhance excitatory synaptic transmission and potentiate NMDA- and AMPA-induced currents in the spinal cord [26]. In addition, the activation of AMPA and/or NMDA receptor is correlated with morphine tolerance and hyperalgesia [27].

Previous reports indicated that free radicals play important roles in the development of opioid analgesic tolerance and radical scavenging agents could be potential tools in the prevention of morphine tolerance [28, 29].

High antioxidant activity of *Satureja khuzestanica* has been demonstrated in numerous reports. Abdollahi and colleagues [30] showed that *satureja* efficiently decreases the normal blood lipid peroxidation level and increases total antioxidant power in rats. It has been shown that 60 days' treatment of diabetic type-2 patients with *Satureja khuzestanica* significantly decreases serum lipids and increases total antioxidant power [31]. Rezvanfar and colleagues [32] reported that *satureja* protects the rat reproductive system from cyclophosphamide-induced toxicity through its antioxidant potential and androgenic activity. Therefore, it seems that the antioxidant property of *satureja* can be, at least in part, responsible for such an inhibiting response (anti-tolerance) in this study. However, this possible mechanism needs to be clarified by further complementary investigation.

However, for evaluating the pharmacological effects of natural products and indicating the validity of the methods used, a standard drug must be simultaneously evaluated as a positive control group, but in this case it is difficult to choose a positive control because of the lack of appropriate standard drugs for morphine tolerance.

In conclusion, this study shows that the ethanolic extract of *Satureja khuzestanica* has significant inhibitory effect against morphine antinociceptive tolerance in rats. Thus, *satureja* may attenuate morphine-induced analgesic tolerance through its ability to decrease spinal cord glia activation. Investigations of the pharmacology of natural products are necessary to gain evidence concerning the usefulness of medicinal plants in phytotherapy. Our experiments therefore contribute to our knowledge of the pharmacology of *Satureja khuzestanica*.

Acknowledgments This work was supported by funds from Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences and Kerman Neuroscience Research Center, Kerman University of Medical Sciences.

Conflict of interest The authors declare that there are no conflicts of interest.

References

1. Stefano GB, Kream RM, Esch T (2009) Revisiting tolerance from the endogenous morphine perspective. *Med Sci Monit* 15:189–198
2. Watkins LR, Hutchinson MR, Milligan ED, Maier SF (2007) “Listening” and “talking” to neurons: implications of immune activation for pain control and increasing the efficacy of opioids. *Brain Res Rev* 56:148–169
3. Raghavendra V, Rutkowski MD, DeLeo JA (2002) The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. *J Neurosci* 22:9980–9989
4. Song P, Zhao ZQ (2001) The involvement of glial cells in the development of morphine tolerance. *Neurosci Res* 39:281–286

5. DeLeo JA, Tanga FY, Tawfik VL (2004) Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. *Neuroscientist* 10:40–52
6. Raghavendra V, Tanga FY, DeLeo JA (2004) Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. *Neuropsychopharmacology* 29:327–334
7. Ward J, Rosenbaum C, Hernon C, McCurdy CR, Boyer EW (2011) Herbal medicines for the management of opioid addiction: safe and effective alternatives to conventional pharmacotherapy? *CNS Drugs* 25:999–1007
8. Zargari A (1990) Medicinal plants. Tehran University Publications, Tehran, pp 42–45
9. Amanlou M, Dadkhah F, Salehnia A, Farsam H, Dehpour AR (2005) An anti-inflammatory and anti-nociceptive effects of hydroalcoholic extract of *Satureja khuzestanica* Jamzad extract. *J Pharm Pharmaceut Sci* 8:102–106
10. Kaeidi A, Esmaeili-Mahani S, Abbasnejad M, Sheibani V, Rasoulilian B, Hajializadeh Z, Pasban-Aliabadi H (2013) *Satureja khuzestanica* attenuates apoptosis in hyperglycemic PC12 cells and spinal cord of diabetic rats. *J Nat Med* 67:61–69
11. Zimmermann M (1983) Ethical guidelines for investigations of experimental pain in conscious animals. *Pain* 16:109–110
12. D'Amour FE, Smith DL (1941) A method of determining loss of pain sensation. *J Pharmacol Exp Ther* 27:74–79
13. Darvishzadeh-Mahani F, Esmaeili-Mahani S, Komeili G, Sheibani V, Zare L (2012) Ginger (*Zingiber officinale* Roscoe) prevents the development of morphine analgesic tolerance and physical dependence in rats. *J Ethnopharmacol* 141:901–907
14. Zare L, Esmaeili-Mahani S, Abbasnejad M, Rasoulilian B, Sheibani V, Sahraei H, Kaeidi A (2012) Oleuropein, chief constituent of olive leaf extract, prevents the development of morphine antinociceptive tolerance through inhibition of morphine-induced L-type calcium channel overexpression. *Phytother Res* 26:1731–1737
15. Zhao J, Xin X, Xie GX, Palmer PP, Huang YG (2012) Molecular and cellular mechanisms of the age-dependency of opioid analgesia and tolerance. *Mol Pain* 8:38
16. Esmaeili Mahani S, Motamedi F, Javan M, Ahmadiani A (2005) Involvement of hypothalamic pituitary adrenal axis on the effects of nifedipine in the development of morphine tolerance in rats. *Pharmacol Biochem Behav* 81:152–157
17. Bryant L, Doyle T, Chen Z, Cuzzocrea S, Masini E, Vinci MC, Esposito E, Mazzon E, Petrusca DN, Petrache I, Salvemini D (2009) Spinal ceramide and neuronal apoptosis in morphine antinociceptive tolerance. *Neurosci Lett* 463:49–53
18. Ueda H, Ueda M (2009) Mechanisms underlying morphine analgesic tolerance and dependence. *Front Biosci* 14:5260–5272
19. Wen YR, Tan PH, Cheng JK, Liu YC, Ji RR (2011) Microglia: a promising target for treating neuropathic and postoperative pain, and morphine tolerance. *J Formos Med Assoc* 110:487–494
20. Tai YH, Wang YH, Wang JJ, Tao PL, Tung CS, Wong CS (2006) Amitriptyline suppresses neuroinflammation and up-regulates glutamate transporters in morphine-tolerant rats. *Pain* 124:77–86
21. Liu CH, Cherng CH, Lin SL, Yeh CC, Wu CT, Tai YH, Wong CS (2011) *N*-Methyl-D-aspartate receptor antagonist MK-801 suppresses glial pro-inflammatory cytokine expression in morphine-tolerant rats. *Pharmacol Biochem Behav* 99:371–380
22. Shen CH, Tsai RY, Shih MS, Lin SL, Tai YH, Chien CC, Wong CS (2011) Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats. *Anesth Analg* 112:454–459
23. Horvath RJ, Romero-Sandoval EA, De Leo JA (2010) Inhibition of microglial P2X4 receptors attenuates morphine tolerance, Iba1, GFAP and mu opioid receptor protein expression while enhancing perivascular microglial ED2. *Pain* 150:401–413
24. Jin H, Li YH, Xu JS, Guo GQ, Chen DL, Bo Y (2012) Lipoxin A4 analog attenuates morphine antinociceptive tolerance, withdrawal-induced hyperalgesia, and glial reaction and cytokine expression in the spinal cord of rat. *Neuroscience* 208:1–10
25. Ndengele MM, Cuzzocrea S, Masini E, Vinci MC, Esposito E, Muscoli C, Petrusca DN, Mollace V, Mazzon E, Li D, Petrache I, Matuschak GM, Salvemini D (2009) Spinal ceramide modulates the development of morphine antinociceptive tolerance via peroxynitrite-mediated nitroxidative stress and neuroimmune activation. *J Pharmacol Exp Ther* 329:64–75
26. Ren K, Dubner R (2010) Interactions between the immune and nervous systems in pain. *Nat Med* 16:1267–1276
27. Guo RX, Zhang M, Liu W, Zhao CM, Cui Y, Wang CH, Feng JQ, Chen PX (2009) NMDA receptors are involved in upstream of the spinal JNK activation in morphine antinociceptive tolerance. *Neurosci Lett* 467:95–99
28. Doyle T, Bryant L, Batinic-Haberle I, Little J, Cuzzocrea S, Masini E, Spasojevic I, Salvemini D (2009) Supraspinal inactivation of mitochondrial superoxide dismutase is a source of peroxynitrite in the development of morphine antinociceptive tolerance. *Neuroscience* 164:702–710
29. Abdel-Zaher AO, Abdel-Rahman MS, ELwasei FM (2010) Blockade of nitric oxide overproduction and oxidative stress by *Nigella sativa* oil attenuates morphine-induced tolerance and dependence in mice. *Neurochem Res* 35:1557–1565
30. Abdollahi M, Salehnia A, Mortazavi SH, Ebrahimi M, Shafiee A, Fouladian F, Keshavarz K, Sorouri S, Khorasani R, Kazemi A (2003) Antioxidant, antidiabetic, antihyperlipidemic, reproduction stimulatory properties and safety of essential oil of *Satureja khuzestanica* in rat in vivo: a oxico-pharmacological study. *Med Sci Monit* 9:331–335
31. Vosough-Ghanbari S, Rahimi R, Kharabaf S, Zeinali S, Mohammadirad A, Amini S, Yasa N, Salehnia A, Toliati T, Nikfar S, Larijani B, Abdollahi M (2010) Effects of *Satureja khuzestanica* on serum glucose, lipids and markers of oxidative stress in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial. *Evid Based Complement Altern Med* 7:465–470
32. Rezvanfar M, Sadrkhanlou R, Ahmadi A, Shojaei-Sadee H, Rezvanfar M, Mohammadirad A, Salehnia A, Abdollahi M (2008) Protection of cyclophosphamide-induced toxicity in reproductive tract histology, sperm characteristics, and DNA damage by an herbal source; evidence for role of free-radical toxic stress. *Hum Exp Toxicol* 27:901–910